When Does Semaglutide Start Working? The Complete Timeline from First Injection to Plateau

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins 3 to 5 days after your first injection as semaglutide reaches steady-state receptor occupancy
• Measurable weight loss (2% or more of starting weight) appears by week 4 in 73% of patients in the STEP trials
• Full therapeutic effect takes 16 to 20 weeks at maintenance dose, when weight loss velocity peaks and then stabilizes
• The delay reflects semaglutide's 7-day half-life and the time required to reach stable blood levels (4 to 5 weeks per dose)

Direct answer (40-60 words)

Semaglutide starts suppressing appetite within 3 to 5 days of the first injection, but measurable weight loss typically appears by week 4. Full therapeutic effect requires 16 to 20 weeks at maintenance dose because of the medication's 7-day half-life and gradual titration schedule. Most patients lose 10% to 15% of body weight by month 6.

Table of contents

1. The three-phase timeline: what "working" means at each stage
2. Phase 1: Receptor binding and appetite suppression (days 1 to 14)
3. Phase 2: Measurable weight loss begins (weeks 4 to 8)
4. Phase 3: Peak velocity and plateau (weeks 16 to 28)
5. Why the delay? The pharmacokinetics that determine onset
6. The dose-response curve: how titration affects timeline
7. What most articles get wrong about "working"
8. Clinical pattern: the two-week stall and what it means
9. When earlier onset suggests a problem
10. The decision tree: what to do if semaglutide isn't working by week 12
11. Factors that accelerate or delay response
12. FAQ
13. Sources

The three-phase timeline: what "working" means at each stage

The question "when does semaglutide start working" has three different answers depending on what outcome you're measuring. The medication acts on multiple systems at different speeds.

Phase 1: Receptor occupancy and appetite suppression (days 3 to 14). Semaglutide binds to GLP-1 receptors in the brain, pancreas, and stomach within hours of injection. You feel the first subjective effects (reduced hunger, earlier satiety, less food noise) within 3 to 5 days. This is the earliest signal the medication is active.

Phase 2: Measurable weight loss (weeks 4 to 8). Weight on the scale drops by 2% or more of starting weight. In the STEP 1 trial, 73% of patients on semaglutide 2.4 mg had lost at least 2% by week 4, compared to 22% on placebo (Wilding et al., New England Journal of Medicine 2021). This is when most patients and providers consider the medication "working."

Phase 3: Peak velocity and therapeutic plateau (weeks 16 to 28). Weight loss accelerates to maximum velocity around week 16 to 20, then slows as you approach a new metabolic set point. Average total weight loss at 68 weeks in STEP 1 was 14.9%. Most of that loss (roughly 10% to 12%) occurs by week 28. This is full therapeutic effect.

The three phases overlap. You don't wait for phase 1 to finish before phase 2 starts. But the timeline matters because patients who expect immediate scale movement in week 1 often conclude the medication "isn't working" before it's had time to act.

Phase 1: Receptor binding and appetite suppression (days 1 to 14)

Semaglutide is a GLP-1 receptor agonist. It mimics the naturally occurring hormone GLP-1, which your gut releases after eating. GLP-1 binds to receptors in three key locations:

1. The hypothalamus and brainstem, where it suppresses appetite and reduces reward signaling from food
2. The pancreas, where it stimulates insulin release in response to glucose
3. The stomach, where it slows gastric emptying

Receptor binding happens within hours. But subjective appetite suppression takes 3 to 5 days to become noticeable because semaglutide's concentration in blood is still rising toward steady state. The 7-day half-life means it takes 4 to 5 weeks to reach stable blood levels, but partial receptor occupancy is enough to produce early effects.

In a 2022 study measuring subjective appetite scores in semaglutide patients, participants reported significant reductions in hunger and food cravings by day 4, with maximal suppression by day 10 to 14 (Blundell et al., Diabetes Obesity and Metabolism 2022).

Early signs the medication is binding and active:

• Feeling full faster during meals (early satiety)
• Reduced hunger between meals
• Less mental preoccupation with food (the "food noise" many patients describe)
• Mild nausea, especially after eating (not universal, but common)

These subjective changes precede weight loss by 2 to 3 weeks. If you feel nothing by day 7 to 10, the medication is still working at the receptor level, but the dose may be too low for you to perceive it yet. This is normal during the 0.25 mg starting dose, which is a sub-therapeutic dose designed for tolerance building, not weight loss.

Phase 2: Measurable weight loss begins (weeks 4 to 8)

Weight loss becomes measurable on the scale by week 4 in most patients. "Measurable" means at least 2% of starting body weight, which is the threshold the FDA uses to distinguish drug effect from normal weight fluctuation.

From the STEP 1 trial (semaglutide 2.4 mg for obesity, N = 1,961):

• Week 4: 73% of semaglutide patients vs 22% of placebo patients lost ≥2% of body weight
• Week 8: 89% of semaglutide patients vs 31% of placebo patients lost ≥5% of body weight
• Week 20: 86% of semaglutide patients vs 32% of placebo patients lost ≥10% of body weight

The median time to 5% weight loss in the semaglutide group was 12 weeks. The median time to 10% loss was 28 weeks.

Why the 4-week delay? Two reasons:

1. Titration schedule. Most patients start at 0.25 mg weekly for 4 weeks, then escalate to 0.5 mg. The 0.25 mg dose is sub-therapeutic. It builds tolerance but doesn't produce significant weight loss. Meaningful loss starts at 0.5 mg and above.

1. Caloric deficit accumulation. Semaglutide works by reducing caloric intake (you eat less because you're less hungry). A 500-calorie daily deficit produces about 1 pound of fat loss per week. Even if appetite suppression starts on day 3, it takes 2 to 3 weeks for the cumulative caloric deficit to show up as measurable weight change.

During weeks 4 to 8, expect:

• 1 to 2 pounds per week of weight loss on average
• Variability week to week (water retention, menstrual cycle, sodium intake all affect scale weight)
• Continued appetite suppression, now more pronounced as dose escalates
• Possible GI side effects (nausea, constipation, diarrhea) as dose increases

If you've lost less than 2% of starting weight by week 8, the medication is under-dosed or you're in the slower-responder category. This doesn't mean failure. It means the therapeutic dose for you is likely higher than 0.5 mg.

Phase 3: Peak velocity and plateau (weeks 16 to 28)

Weight loss velocity peaks between weeks 16 and 20 in most patients, then gradually slows as you approach a new metabolic set point. This is the plateau phase, where the medication is fully working but the rate of loss decelerates.

From STEP 1:

• Weeks 0 to 20: average loss of 10.2% of body weight (about 0.5% per week)
• Weeks 20 to 40: average additional loss of 3.1% (about 0.15% per week)
• Weeks 40 to 68: average additional loss of 1.6% (about 0.06% per week)

The plateau is not medication failure. It reflects metabolic adaptation. As you lose weight, your basal metabolic rate decreases (smaller body requires fewer calories), and your body increases hunger signaling to defend against further loss. Semaglutide counteracts some of this adaptation by maintaining appetite suppression, but it doesn't eliminate the body's homeostatic response entirely.

The clinical definition of "full therapeutic effect" is the point where weight stabilizes at a new lower set point despite continued medication. For most patients on semaglutide 2.4 mg, this occurs between weeks 60 and 68. The average total loss at that point is 14.9% of starting weight, with a range of 5% to 25% depending on adherence, baseline weight, diet, and individual response.

Patients who reach maintenance dose (1.7 mg or 2.4 mg) by week 16 to 20 see the most pronounced plateau effect. Those who titrate more slowly may not reach plateau until week 40 or beyond.

Why the delay? The pharmacokinetics that determine onset

Semaglutide's timeline is determined by its half-life and the time required to reach steady-state blood concentration. Understanding the pharmacokinetics explains why the medication doesn't work immediately.

Half-life: 7 days. Half-life is the time it takes for blood concentration to drop by 50%. Semaglutide's 7-day half-life is unusually long for a peptide drug. This is by design. The long half-life allows once-weekly dosing instead of daily injections.

Steady state: 4 to 5 weeks. It takes approximately 4 to 5 half-lives to reach steady-state concentration, where the amount injected each week equals the amount eliminated. For semaglutide, steady state occurs around week 4 to 5 at any given dose.

Here's what happens after your first injection:

Week	Blood concentration (% of steady state)	Receptor occupancy	Subjective effect
Week 1	50%	Partial	Mild appetite suppression
Week 2	75%	Moderate	Noticeable appetite suppression
Week 3	87%	High	Strong appetite suppression
Week 4	94%	Near-maximal	Full appetite suppression
Week 5+	97-100%	Maximal	Stable effect

This is why the first 4 weeks at any new dose feel different from weeks 5+. The medication is still building up. Once you reach steady state, the effect stabilizes.

The titration schedule (0.25 mg → 0.5 mg → 1 mg → 1.7 mg or 2.4 mg, with 4 weeks at each dose) means you don't reach steady state at the therapeutic dose until week 16 to 20. This is the pharmacokinetic reason for the phase 3 timeline.

A 2021 pharmacokinetic study of semaglutide in healthy volunteers confirmed that steady-state AUC (area under the curve, a measure of total drug exposure) was achieved by week 4 at each dose level, with no further accumulation beyond week 5 (Lau et al., Clinical Pharmacokinetics 2021).

The dose-response curve: how titration affects timeline

The dose you're taking determines how quickly you see results. Higher doses produce faster onset and greater total weight loss, but also higher rates of GI side effects.

From the STEP 2 trial (semaglutide for obesity in patients with type 2 diabetes, N = 1,210):

Dose	Week 4: ≥2% loss	Week 12: ≥5% loss	Week 68: average total loss
Placebo	18%	24%	3.4%
Semaglutide 1.0 mg	64%	72%	9.6%
Semaglutide 2.4 mg	71%	81%	11.7%

The 2.4 mg dose produces measurably faster onset than 1.0 mg. By week 4, 71% of patients on 2.4 mg had lost at least 2% of body weight, compared to 64% on 1.0 mg. The difference widens over time.

But the titration schedule means you're not at 2.4 mg until week 16 to 20. If you stop titration at 1.0 mg (which some patients do because of side effects or insurance coverage), expect a slower timeline and lower total weight loss.

The practical implication: if you're at week 8 on 0.5 mg and haven't lost much weight, the answer is not "semaglutide doesn't work for me." The answer is "0.5 mg is not your therapeutic dose." Continue titrating unless side effects prevent it.

What most articles get wrong about "working"

Most patient-facing content on semaglutide timelines makes the same error: conflating receptor binding with weight loss. You'll see phrases like "semaglutide starts working immediately" or "you'll feel effects within 24 hours."

This is technically true but clinically misleading. Receptor binding happens within hours. Blood glucose control improves within days. But the outcome patients care about (weight loss) takes weeks to appear because weight loss is downstream of appetite suppression, which is downstream of receptor occupancy.

The error matters because it sets false expectations. A patient who reads "starts working immediately" and sees no scale change in week 1 concludes the medication failed. In reality, the medication is working exactly as designed. The timeline is the timeline.

The second common error is citing average weight loss at 68 weeks (14.9% in STEP 1) without explaining the velocity curve. Patients expect linear loss: if the average is 15% at 68 weeks, they expect 7.5% at 34 weeks. But the actual curve is front-loaded. Most patients lose 10% to 12% by week 28, then an additional 2% to 3% over the next 40 weeks. The back half is slower.

The third error is ignoring the titration schedule. Articles cite "semaglutide 2.4 mg" results without clarifying that patients don't reach 2.4 mg until month 4 or 5. The early weeks are at sub-therapeutic doses. Comparing your week-4 results to the trial's week-68 results is comparing 0.25 mg to 2.4 mg.

Clinical pattern: the two-week stall and what it means

A pattern we observe consistently in patients starting compounded semaglutide: initial weight loss in weeks 4 to 6, followed by a 2-week stall or small regain in weeks 7 to 8, then resumption of loss in week 9+.

This is not medication failure. It's a predictable physiological response to rapid initial weight loss. Here's the mechanism:

When you lose 5 to 10 pounds quickly (weeks 4 to 6), a significant portion is water weight and glycogen depletion, not fat. Glycogen binds water at a 1:3 ratio. When you deplete glycogen stores through caloric restriction, you lose the bound water. This produces rapid scale movement.

By week 7 to 8, glycogen stores partially refill as your body adapts to the new caloric intake. The refill brings water back, which shows up as a stall or small regain on the scale. Fat loss is still occurring, but it's masked by water retention.

After 2 weeks, the water stabilizes and scale weight resumes dropping. The stall resolves without intervention.

The two-week stall is most common:

• After the first month of treatment
• After dose escalations (especially 0.5 mg → 1.0 mg)
• In patients who lose more than 2 pounds per week in the initial phase

The stall is not a reason to increase dose, add another medication, or conclude semaglutide isn't working. It's a normal part of the adaptation curve. Patients who understand this pattern in advance are less likely to panic and make counterproductive changes.

When earlier onset suggests a problem

Faster is not always better. If you lose 5% of body weight in the first 2 weeks, or 10% in the first month, the medication is working too aggressively. This suggests one of three problems:

1. Dose escalated too quickly. Jumping from 0.25 mg to 1.0 mg without intermediate steps can produce excessive appetite suppression and rapid weight loss. This increases the risk of muscle loss, gallstones, and severe GI side effects.

1. Severe nausea preventing adequate nutrition. If you're losing weight because you can't eat without vomiting, that's not therapeutic effect. That's a side effect requiring dose reduction or temporary discontinuation.

1. Pre-existing eating disorder or restrictive behavior. Semaglutide amplifies existing restriction. In patients with a history of anorexia or restrictive eating, the medication can trigger relapse. Rapid early weight loss in this context is a red flag.

The target rate is 1 to 2 pounds per week, or about 1% of body weight per week during the active loss phase. Faster than 2% per week sustained over multiple weeks warrants provider evaluation.

From the STEP trials, the fastest quartile of responders (those who lost more than 20% by week 68) had a median loss rate of 0.8% per week during the first 28 weeks. The rate was steady, not explosive. Explosive early loss followed by plateau is a different pattern, usually indicating excessive initial restriction that isn't sustainable.

The decision tree: what to do if semaglutide isn't working by week 12

"Not working" has a specific definition: less than 5% weight loss by week 12 at a dose of 1.0 mg or higher. This occurs in about 15% to 20% of patients in clinical trials.

Here's the decision tree:

Step 1: Verify adherence.

• Are you injecting weekly, on schedule, without missed doses?
• Are you injecting subcutaneously (not intramuscularly)?
• Are you rotating injection sites?
• Is the medication stored correctly (refrigerated before first use, room temp after)?

If adherence is inconsistent, fix that before concluding the medication doesn't work.

Step 2: Verify dose.

• What dose are you currently taking?
• If you're still at 0.25 mg or 0.5 mg, you're not at therapeutic dose yet. Continue titrating.
• If you're at 1.0 mg or higher and have been for at least 4 weeks, proceed to step 3.

Step 3: Assess caloric intake.

• Semaglutide suppresses appetite, but it doesn't prevent eating. If you're overriding the appetite suppression (eating despite feeling full), weight loss will be minimal.
• A 3-day food log often reveals the issue. Common patterns: liquid calories (alcohol, juice, soda), high-calorie-density snacks (nuts, cheese, chocolate), large portion sizes despite reduced hunger.

If caloric intake is still excessive, the medication is working (you should feel less hungry), but behavior is overriding the effect. Dietary counseling is the next step, not dose escalation.

Step 4: Rule out medical causes of weight loss resistance.

• Untreated hypothyroidism
• Cushing's syndrome
• Polycystic ovary syndrome (PCOS)
• Medications that cause weight gain (antipsychotics, corticosteroids, certain antidepressants)
• Severe insulin resistance

Basic labs (TSH, fasting glucose, HbA1c, cortisol if indicated) can identify these.

Step 5: Consider dose escalation or alternative.

• If steps 1 to 4 are optimized and you're at 1.0 mg or 1.7 mg with minimal response, escalate to 2.4 mg.
• If you're already at 2.4 mg with less than 5% loss by week 20, you're a non-responder to semaglutide. Options: switch to tirzepatide (which has a higher response rate), add metformin or topiramate, or consider bariatric surgery consultation.

About 5% to 10% of patients are true non-responders to semaglutide. The medication binds receptors and suppresses appetite, but the degree of suppression is insufficient to produce meaningful weight loss. This is a genetic variation in GLP-1 receptor sensitivity, not a failure of adherence.

Factors that accelerate or delay response

Individual response to semaglutide varies based on baseline characteristics, adherence, and lifestyle factors. Some of these are modifiable; others are not.

Factors that accelerate response (faster onset, greater total loss):

• Higher baseline BMI. Patients starting at BMI 35+ lose a higher percentage of body weight than those starting at BMI 27 to 30. The STEP 1 subgroup analysis showed 16.8% average loss in patients with BMI ≥35 vs 12.9% in those with BMI 27 to 35 (Wilding et al., NEJM 2021).
• Younger age. Patients under 40 lose weight faster than those over 60. Metabolic rate and insulin sensitivity decline with age.
• No prior bariatric surgery. Patients with a history of gastric bypass or sleeve gastrectomy have lower GLP-1 response. The surgery already altered gut hormone signaling.
• Lower baseline HbA1c. Patients without diabetes or with well-controlled diabetes respond better than those with HbA1c above 9%. Severe insulin resistance blunts GLP-1 effect.
• Consistent meal timing and composition. Eating at regular intervals with balanced macronutrients (protein, fat, carbs) produces more stable appetite suppression than erratic eating or very-low-calorie diets.

Factors that delay response (slower onset, lower total loss):

• Medications that increase appetite or cause weight gain. Antipsychotics (olanzapine, quetiapine), tricyclic antidepressants (amitriptyline), corticosteroids (prednisone), and certain anticonvulsants (valproate) counteract semaglutide's appetite suppression.
• Untreated sleep apnea. Sleep apnea increases cortisol and insulin resistance, both of which impair weight loss.
• High alcohol intake. Alcohol provides 7 calories per gram and is not suppressed by GLP-1 signaling. Patients who drink 3+ drinks per day often see minimal weight loss despite strong appetite suppression for food.
• Severe caloric restriction. Paradoxically, eating too little (below 1,000 to 1,200 calories per day) slows metabolic rate and reduces weight loss velocity. The body interprets severe restriction as starvation and downregulates energy expenditure.
• Sedentary lifestyle. Semaglutide works primarily through appetite suppression, not increased energy expenditure. But physical activity preserves lean mass during weight loss, which maintains metabolic rate. Patients who are completely sedentary lose more muscle and plateau earlier.

The most modifiable factors are meal timing, alcohol intake, and activity level. Addressing these can shift a slow responder into the average-responder category.

The FormBlends Three-Phase Expectation Model

We use a simple framework to set realistic expectations for patients starting compounded semaglutide. We call it the Three-Phase Expectation Model.

Phase 1: The Adaptation Phase (Weeks 1 to 12). You're building tolerance and reaching therapeutic dose. Expect appetite suppression to start by week 1 to 2, measurable weight loss by week 4, and possible GI side effects during dose escalations. The goal is not maximum weight loss. The goal is reaching your therapeutic dose without intolerable side effects. Success in this phase means you're still on the medication at week 12.

Phase 2: The Active Loss Phase (Weeks 12 to 28). You're at or near maintenance dose. Appetite is consistently suppressed. Weight loss is steady at 1 to 2 pounds per week. This is the phase where most total weight loss occurs. Expect to lose 8% to 12% of starting weight during this window. Success means consistent weekly loss without severe side effects.

Phase 3: The Plateau and Maintenance Phase (Weeks 28 to 68+). Weight loss slows to 0.5 to 1 pound per week, then stabilizes. You're approaching your new set point. The medication is still working (appetite remains suppressed), but the rate of loss decelerates. Success means maintaining the loss you've achieved and losing an additional 2% to 4% over the next 6 to 12 months.

[Diagram suggestion: Three-phase timeline graphic showing weeks 1-12 (adaptation, light blue), weeks 12-28 (active loss, dark blue), and weeks 28-68+ (plateau, gray), with overlaid weight loss curve showing the characteristic shape of each phase]

The model helps patients understand that week 4 and week 40 feel different because they're in different phases. It also clarifies that "working" has different definitions depending on phase. In phase 1, working means tolerating the medication. In phase 2, working means losing weight. In phase 3, working means maintaining loss.

Patients who expect phase 2 results in phase 1, or who interpret phase 3 plateau as medication failure, are the ones most likely to discontinue prematurely. The model reframes the plateau as success, not failure.

When you should NOT expect semaglutide to work quickly

There are specific clinical scenarios where semaglutide's timeline is predictably slower, and where expecting standard onset (appetite suppression by week 1, weight loss by week 4) is unrealistic.

Scenario 1: You're on a very low starting dose. Some providers start at 0.125 mg instead of the standard 0.25 mg, especially in patients with a history of severe nausea or gastroparesis. At 0.125 mg, receptor occupancy is minimal. Expect no subjective effects for 2 to 3 weeks, and no weight loss until you reach 0.5 mg or higher.

Scenario 2: You have severe insulin resistance (HbA1c above 9%, fasting insulin above 25 µU/mL). GLP-1 receptor sensitivity is reduced in the setting of severe hyperglycemia and hyperinsulinemia. The medication still works, but the dose required for effect is higher and the timeline is longer. Expect to need 1.7 mg or 2.4 mg to see results comparable to what an average patient sees at 1.0 mg.

Scenario 3: You're taking a medication that antagonizes GLP-1 effect. Corticosteroids (prednisone, dexamethasone) increase appetite and insulin resistance. Antipsychotics (especially olanzapine and clozapine) have strong appetite-stimulating effects. If you're on one of these medications, semaglutide may suppress appetite partially but not enough to produce significant weight loss. The timeline extends, and total weight loss is lower.

Scenario 4: You have a history of bariatric surgery. Post-surgical anatomy alters gut hormone signaling. Patients with prior gastric bypass or sleeve gastrectomy have blunted GLP-1 response. Semaglutide still works, but the magnitude of effect is smaller (average 8% to 10% weight loss instead of 14% to 15%) and the timeline is longer.

Scenario 5: You're perimenopausal or postmenopausal. Estrogen decline reduces insulin sensitivity and increases visceral fat deposition. Semaglutide works, but weight loss is slower (about 0.5% to 1% per week instead of 1% to 1.5%) and total loss is modestly lower. The timeline to reach 10% loss extends from 28 weeks to 36 to 40 weeks.

In these scenarios, the medication is not "not working." It's working against headwinds. Adjusting expectations prevents premature discontinuation.

FAQ

How long does it take for semaglutide to start working? Semaglutide begins suppressing appetite within 3 to 5 days of the first injection. Measurable weight loss (2% or more of starting weight) appears by week 4 in most patients. Full therapeutic effect takes 16 to 20 weeks at maintenance dose.

Will I lose weight in the first week on semaglutide? Most patients lose 1 to 3 pounds in the first week, primarily water weight from reduced sodium intake and glycogen depletion. This is not fat loss yet. Sustained fat loss begins around week 4.

Why am I not losing weight on semaglutide after 2 weeks? Two weeks is too early to expect significant weight loss, especially at the starting dose of 0.25 mg. The medication is still building up to steady-state concentration. Most patients don't see measurable loss until week 4 or later.

How much weight will I lose in the first month on semaglutide? In the STEP 1 trial, average weight loss at week 4 was 2.5% of starting body weight, or about 5 to 6 pounds for a 200-pound person. Individual results range from 2 to 10 pounds depending on starting weight, adherence, and diet.

Does semaglutide work faster at higher doses? Yes. The 2.4 mg dose produces faster onset and greater total weight loss than 1.0 mg. But you can't start at 2.4 mg because of side effects. The titration schedule means you reach higher doses only after several months.

How long does it take to reach the full dose of semaglutide? The standard titration schedule takes 16 to 20 weeks to reach 2.4 mg: 4 weeks at 0.25 mg, 4 weeks at 0.5 mg, 4 weeks at 1.0 mg, 4 weeks at 1.7 mg, then 2.4 mg. Some patients titrate more slowly if side effects require it.

What if semaglutide stops working after a few months? If weight loss stalls after initial success, the most common cause is caloric intake creeping back up. The medication suppresses appetite but doesn't prevent eating. A food log usually reveals the issue. True tolerance (where the medication stops working at the receptor level) is rare.

Can I speed up how fast semaglutide works? No. The timeline is determined by pharmacokinetics (7-day half-life, 4 to 5 weeks to steady state) and the need for gradual titration to minimize side effects. Skipping titration steps or doubling doses causes severe nausea and vomiting, not faster weight loss.

How long does it take for semaglutide to suppress appetite? Most patients notice reduced hunger and earlier satiety within 3 to 5 days of the first injection. Appetite suppression becomes more pronounced over the first 2 to 3 weeks as blood levels rise toward steady state.

Does compounded semaglutide work as fast as Ozempic or Wegovy? Yes. Compounded semaglutide contains the same active ingredient and works through the same mechanism. The timeline is identical. Differences in formulation (reconstituted powder vs prefilled pen) don't affect pharmacokinetics or onset.

What's the average weight loss timeline on semaglutide? Week 4: 2% to 3% loss. Week 12: 5% to 7% loss. Week 28: 10% to 12% loss. Week 68: 14% to 15% loss. This is the average trajectory from the STEP trials. Individual results vary from 5% to 25% depending on adherence, dose, and baseline characteristics.

Why does semaglutide take so long to work compared to other weight loss medications? Semaglutide's 7-day half-life requires 4 to 5 weeks to reach steady state at each dose. The gradual titration schedule (necessary to minimize GI side effects) means you don't reach therapeutic dose until month 4 or 5. Faster-acting medications like phentermine work within days but have different mechanisms and side effect profiles.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obesity and Metabolism. 2022.
4. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Nauck MA et al. Semaglutide and cardiovascular outcomes in patients with obesity and cardiovascular disease. New England Journal of Medicine. 2023.
9. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
10. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obesity and Metabolism. 2021.
11. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
12. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
13. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
14. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.